None
Quote | Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX)
Last: | $41.85 |
---|---|
Change Percent: | -1.04% |
Open: | $42.49 |
Close: | $42.29 |
High: | $42.865 |
Low: | $41.69 |
Volume: | 340,227 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX)
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its c...
2024-04-03 11:37:09 ET More on Crinetics Pharmaceuticals Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript Crinetics gains as late-stage trial for lead drug succeeds...
Message Board Posts | Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Crinetics Pharmaceuticals Inc. Company Name:
CRNX Stock Symbol:
NASDAQ Market:
Crinetics Pharmaceuticals Inc. Website:
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its c...
Tuesday, Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) released topline results from PATHFNDR-2, the second of two Phase 3 studies evaluati...
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS...